Evidence map›Paper›PMID 34290074›Full record

ArticleCancer discovery2021

Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective.

Keith T Flaherty, James H Doroshow, Susan Galbraith, Antoni Ribas, Paul G Kluetz, Richard Pazdur, Marc R Theoret

Abstract read
In one paragraph

Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals during COVID-19.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  5. Improving Collection and Analysis of Overall Survival Data.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Core Concept: In the wake of COVID-19, decentralized clinical trials move to center stage.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Keith T FlahertyMassachusetts General Hospital Cancer Center, Boston, Massachusetts. kflaherty@mgh.harvard.edu.
James H DoroshowNCI, NIH, Bethesda, Maryland.ORCID 0000-0002-4463-1790
Susan GalbraithAstraZeneca, Los Angeles, California.
Antoni RibasJonsson Comprehensive Cancer Center at the University of California, Los Angeles (UCLA), Los Angeles, California.
Paul G KluetzOncology Center of Excellence, Food and Drug Administration, Silver Spring, Maryland.
Richard PazdurOncology Center of Excellence, Food and Drug Administration, Silver Spring, Maryland.
Marc R TheoretOncology Center of Excellence, Food and Drug Administration, Silver Spring, Maryland.

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Project 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORICEAU, GATIEN P · 2020 to 2024
$12.8M
Next Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4M
Phase 01 Clinical TrialsZIABC011078 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI DOROSHOW, JAMES · 2009 to 2025
$9.0M
NCI NIH HHS P01 CA244118NCI NIH HHS P30 CA016042NCI NIH HHS R35 CA197633
6 · The paper itself

Abstract

The COVID-19 pandemic brought about major changes in cancer clinical trials. In its aftermath, the community has an opportunity to incorporate some of these changes as part of the future of trial conduct to make it more patient centered.

Indexed as

Clinical Trials as TopicCOVID-19NeoplasmsAcademies and InstitutesDrug IndustryGovernment AgenciesHumansInfection ControlNational Cancer Institute (U.S.)United StatesUnited States Food and Drug Administration

Identifiers

PMID34290074
PMCPMC8340848

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.